GlassScriptPhysician profile
Ajay Jain
NPI 1063426674
$47,448.40
in general payments reported to CMS, 2019-2025
50 companies · $4,577 in 2025
The $4,577 reported for 2025 was more than what 87% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,546 · 2020: $4,340 · 2021: $8,378 · 2022: $13K · 2023: $11K · 2024: $3,885 · 2025: $4,577.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $10K · Food and Beverage: $8,920 · Travel and Lodging: $53.71 · Education: $13.20.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $10,100.00 |
| Food and Beverage | $8,919.88 |
| Travel and Lodging | $53.71 |
| Education | $13.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $31,153.93 | 2019-2025 | Breztri, Fasenra, Airsupra |
| Glaxosmithkline, LLC. | $3,167.42 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Inspire Medical Systems, INC. | $2,439.01 | 2022-2025 | Inspire |
| Actelion Pharmaceuticals US, INC. | $1,641.13 | 2019-2025 | Uptravi, Opsumit, Opsynvi |
| Regeneron Healthcare Solutions, INC. | $1,007.57 | 2021-2025 | Dupixent |
| Genzyme Corporation | $990.63 | 2019-2025 | |
| Mallinckrodt Hospital Products INC. | $873.20 | 2020-2025 | Acthar |
| Electromed, INC. | $601.99 | 2019-2025 | Smartvest |
| Philips North America LLC | $580.46 | 2019-2025 | Vest Therapy Und, (Ak6) Vest Therapy |
| Takeda Pharmaceuticals U.S.A., INC. | $531.86 | 2020-2025 | Aralast |
| Janssen Pharmaceuticals, INC | $412.60 | 2019-2023 | Xarelto |
| Sunovion Pharmaceuticals INC. | $338.25 | 2019-2021 | |
| Mylan Specialty L.P. | $228.17 | 2019-2024 | Yupelri |
| Zoll Respicardia, INC. | $221.64 | 2021-2024 | Remede System |
| Axsome Therapeutics, INC. | $215.41 | 2022-2025 | Sunosi |
Show all 49 companies
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ajay Jain listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.